Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,886 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of Mayo Adhesive Probability Score With Perioperative Outcomes and Histological Characteristics of Adherent Perinephric Fat in Laparoscopic Adrenalectomy.
Miyamoto T, Hori S, Onishi S, Tomizawa M, Shimizu T, Onishi K, Morizawa Y, Gotoh D, Nakai Y, Miyake M, Trimoto K, Tanaka N, Fujimoto K. Miyamoto T, et al. Among authors: miyake m. In Vivo. 2024 Nov-Dec;38(6):2836-2843. doi: 10.21873/invivo.13764. In Vivo. 2024. PMID: 39477434 Free PMC article.
Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy.
Kirisawa T, Shiota M, Kimura T, Edamura K, Miyake M, Morizane S, Yoshino T, Matsukawa A, Matsumoto R, Kasahara T, Nishiyama N, Eto M, Kitamura H, Nakamura E, Matsui Y; Japanese Urological Oncology Group. Kirisawa T, et al. Among authors: miyake m. Int J Clin Oncol. 2023 Feb;28(2):306-313. doi: 10.1007/s10147-022-02278-7. Epub 2022 Dec 17. Int J Clin Oncol. 2023. PMID: 36527579
Efficacy and safety of second-line cabozantinib after immuno-oncology combination therapy for advanced renal cell carcinoma: Japanese multicenter retrospective study.
Sazuka T, Matsushita Y, Sato H, Osawa T, Hinata N, Hatakeyama S, Numakura K, Ueda K, Kimura T, Takahashi M, Tanaka H, Kawasaki Y, Kurahashi T, Kato T, Fujita K, Miyake M, Kojima T, Kitamura H, Miyake H, Ichikawa T. Sazuka T, et al. Among authors: miyake h, miyake m. Sci Rep. 2023 Nov 23;13(1):20629. doi: 10.1038/s41598-023-48087-4. Sci Rep. 2023. PMID: 37996622 Free PMC article.
External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma.
Hamamoto S, Tasaki Y, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Sugiyama Y, Taguchi K, Yasui T. Hamamoto S, et al. Among authors: miyake m. Front Oncol. 2024 Sep 2;14:1400041. doi: 10.3389/fonc.2024.1400041. eCollection 2024. Front Oncol. 2024. PMID: 39286026 Free PMC article.
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Peltola K, de Velasco G, Burotto M, Suarez C, Ghatalia P, Iacovelli R, Lam ET, Verzoni E, Gümüş M, Stadler WM, Kollmannsberger C, Melichar B, Venugopal B, Gross-Goupil M, Poprach A, De Santis M, Schutz FA, Park SH, Nosov DA, Porta C, Lee JL, Garcia-Del-Muro X, Biscaldi E, Manneh Kopp R, Oya M, He L, Wang A, Perini RF, Vickery D, Albiges L, Rini B; LITESPARK-005 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Aug 22;391(8):710-721. doi: 10.1056/NEJMoa2313906. N Engl J Med. 2024. PMID: 39167807 Clinical Trial.
1,886 results